News
EU launches initiative to improve reproductive health and rights in Africa
The commitment is part of the EU-Africa Global Gateway package and the EU Global Health Strategy
The EU alongside three African regional economic communities have announced a new initiative to improve reproductive health and rights in Africa.
The European and African partners are aiming to improve sexual and reproductive health and rights (SRHR), particularly among adolescent girls and young women, to empower and enable them to reach their full potential.
The initiative, which is hoped to enhance coordination and collaboration among partners, was launched in Kigali, Rwanda on December 15 and is part of the EU-Africa Global Gateway package and the EU Global Health Strategy.
According to the European Commission, the new initiative builds on a joint analysis of gaps, needs, and lessons learnt, and prioritises areas where a regional perspective can complement global and country level investments, with a focus on increasing the implementation of continental and regional commitments on SRHR in the health and education sector, improving the availability, affordability and acceptability of SRHR goods and strengthening advocacy and accountability.
The pandemic has had a strong negative impact on SRHR in Africa. Reports suggest further action is needed to make available information on SRHR, goods and services and accelerate progress on key issues such as family planning, the fight against gender-based violence, harmful practices, maternal mortality and sexual health and well-being.
“In line with the new EU Global Health Strategy, empowering women, girls and young people by investing in their health and education is key to building prosperous and inclusive societies,” said Commissioner for International Partnerships, Jutta Urpilainen.
“I am proud to launch, as a key follow-up of the AU-EU Summit, this Africa–EU partnership initiative and collaborative framework to advance our shared, strong commitment to realise sexual and reproductive health and rights for all and ensure that we deliver with more impact where it is needed.”
“Together with our European and African partners, we want to make sure that everyone in Sub Saharan Africa, whatever their gender, age or sex, can make their own choices about their body, health and future,” added Frank Vandenbroucke, Deputy Prime Minister and Minister of Social Affairs and Public Health of Belgium, in charge of Development Cooperation and Major Cities Policy.
“With 70 per cent of the region’s population being under the age of 30, it is crucial that younger generations have access to sexual and reproductive health services and information.
“Our expertise and experience in education and health, particularly with regards to Universal Health Coverage, as well as the long-standing cooperation with our African partners are strong assets that will undoubtedly contribute to the SRHR Agenda in Sub Saharan Africa and to establishing universal access to sexual and reproductive health care and rights, especially for young girls and women.”
Birgit Pickel, director general for Africa, German Federal Ministry for Economic Cooperation and Development, said: “Health is a human right. Improving access to reproductive health services has an impact particularly on the lives of women and girls that goes far beyond the health sector.
“Qualitative reproductive health services are thus fundamental to achieving gender equality and to promoting the social, economic, and political participation of women.
Anne-Claire Amprou, Ambassador for Global Health, French Ministry of Europe and Foreign Affairs, stressed that promoting sexual and reproductive health and rights must be a priority.
“It is indeed at the cornerstone of gender equality and human rights, which are also the foundations of our feminist diplomacy.”
Funding from the EU budget includes €60m in new funds for 2023–2027 and EU member states are expected to make new financial commitments in the coming years.
The initiative has been developed by the European Commission, the EU Member States Belgium, Czech Republic, Denmark, Finland, France, Germany, Ireland, Luxemburg, Netherlands and Sweden, and three African regional economic communities: the East African Community (EAC), the West African Health Organization (WAHO) of the Economic Community of West African States (ECOWAS) and the Southern African Development Community (SADC).
The commission says the move will be taken forward in partnership with a range of additional stakeholders, including governments, civil society organisations, private sector, academic institutions and the United Nations.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Hormonal health2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment